"
Team:Wageningen UR/Summary
From 2013.igem.org
Jingjing4028 (Talk | contribs) |
Jingjing4028 (Talk | contribs) |
||
| Line 40: | Line 40: | ||
<div class="content summary"> | <div class="content summary"> | ||
<h1>Summary</h1> | <h1>Summary</h1> | ||
| - | <h2> | + | <h2>What we've achieved and what's to come</h2> |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 19:35, 4 October 2013
- Safety introduction
- General safety
- Fungi-related safety
- Biosafety Regulation
- Safety Improvement Suggestions
- Safety of the Application
Summary
What we've achieved and what's to come
Concluding our iGEM project in 2013, we introduced Aspergillu Niger as a potential host into iGEM. With the host engineering, we stepped further to the next level of synthetic biology. In this GRAS organism, we established a modular system of domain shuffling in order to express a variety of secondary metabolites. The lovastatin as a crucial compound in medical industry was further studied and the domains of its key enzyme was assembled and modular. Via the modularity approach, their physiology was modified to some extent to comply the need of industry. Additionally, to target the production of specific compartment, a toolkit including pH sensor, ATP sensor and visible chromoprotein display was created successfully. It accelerated the exploration of more potentiality.
For the further study, we recommend to make the toolkit more completed and increase the repertoire with new part and devices. And our mix-match assembling method can be better improved to produce much more valuable secondary metabolites.
